We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
Bayer AG (BAYN.XE) said Thursday that it is investing up to $100 million to research new treatments for cardiovascular and gynecological diseases with U.S. biotech Dewpoint Therapeutics.
The two companies signed an option, research and license agreement, Bayer said. Under the terms of the deal it will use Dewpoint's biomolecular condensates platform to drive research into the disease areas.
Germany's Bayer also said that it will have the option to exclusively license new therapy candidates developed from the research activities.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 14, 2019 08:47 ET (13:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
